Physician profile
David Sire
NPI 1710046628
$7,196.80
in general payments reported to CMS, 2019-2025
35 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $409 · 2021: $663 · 2022: $782 · 2023: $1,450 · 2024: $1,913 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,273.95 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.49 | 2020-2025 | Botox, Skyrizi |
| Pfizer INC. | $759.68 | 2019-2025 | |
| Galderma Laboratories, L.P. | $713.85 | 2019-2025 | Nemluvio, Dysport |
| Genzyme Corporation | $648.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $574.60 | 2022-2025 | Dupixent |
| Incyte Corporation | $525.95 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $457.81 | 2020-2025 | Absorica Ld, Winlevi |
| Biofrontera INC. | $290.77 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $245.86 | 2019-2025 | |
| Allergan, INC. | $243.94 | 2019-2021 | |
| Leo Pharma INC. | $233.15 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $209.98 | 2023-2025 | Tremfya |
| Merz North America, INC. | $170.36 | 2019-2020 | |
| Ucb, INC. | $124.87 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $118.88 | 2023-2024 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $95.70 | 2023-2025 | Klisyri, Seysara |
| Prugen, INC. Pharmaceuticals | $89.28 | 2020 | |
| Arcutis Biotherapeutics, INC. | $80.70 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.19 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $74.92 | 2024-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.25 | 2023-2024 | Spevigo |
| Bioventus LLC | $41.28 | 2022 | |
| Lilly USA, LLC | $41.21 | 2024 | Olumiant |
| Mimedx Group, INC. | $40.91 | 2024 | |
| Mayne Pharma Commercial LLC | $37.57 | 2023 | |
| Amgen INC. | $32.40 | 2024 | Otezla |
| Botanix Sb INC | $26.81 | 2025 | Sofdra |
| Lumenis, INC | $25.04 | 2021 | |
| Sensus Healthcare, INC. | $24.41 | 2019 | |
| Dermira, INC. | $21.96 | 2019 | |
| Journey Medical Corporation | $19.95 | 2022 | |
| Organon LLC | $19.89 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $19.20 | 2019 | |
| Misonix INC | $18.28 | 2021 | |
| Aclaris Therapeutics, INC. | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.